How to Help Your Patients Save Money on Finacea: A Provider's Guide to Savings Programs

Prescription cost is one of the most common reasons patients abandon rosacea treatment before it has a chance to work. Finacea (azelaic acid 15%) has a wide price range — the brand-name foam can retail at over $600 per supply without insurance, while the generic gel can be as low as $27 with the right coupon. As the prescribing provider, you have significant influence over which price point your patient encounters. This guide outlines every available savings mechanism and the specific prescribing strategies that lead to the best patient outcomes and lowest abandonment rates.

Why Prescription Abandonment Matters for Rosacea

Rosacea is a chronic condition requiring long-term topical therapy. A patient who abandons treatment after one failed insurance claim or one sticker-shock moment at the pharmacy will not achieve the symptom control that clinical trials demonstrate. Proactively addressing cost at the time of prescribing — by choosing the right formulation, the right generic, and the right savings program — significantly increases treatment adherence.

Strategy 1: Default to Generic Azelaic Acid 15% Gel

The most impactful single step is prescribing the generic by name: "azelaic acid 15% gel, 50g, generic acceptable." This has multiple downstream benefits:

Retail price of the generic ($100–$260) is substantially lower than brand-name Finacea foam ($400–$600+).

With GoodRx or SingleCare coupons, the generic gel drops to $27–$50 at most major chains.

Generic prescriptions typically face fewer PA requirements than brand-name Finacea.

Generic azelaic acid 15% gel is more widely stocked at pharmacies, reducing the chance the patient can't fill the prescription at all.

Strategy 2: Inform Patients About Discount Coupons at the Visit

A brief mention at the point of prescribing can prevent prescription abandonment. Tell patients: "If your insurance doesn't cover this or the copay seems high, check GoodRx or SingleCare — you can get the generic for around $27–$38."

Consider including a printed handout or notation in the visit summary with instructions on how to use GoodRx or SingleCare. Patients often don't know these tools exist, or assume they require enrollment or fees. Clarify that they are free cards that can be shown at the pharmacy counter.

Strategy 3: LEO Pharma Savings Card (Brand Finacea Foam)

If you have a clinical reason to prescribe the foam (e.g., patient with very sensitive skin who doesn't tolerate the gel's burning and stinging), the brand-name Finacea foam's cost can be managed through the LEO Pharma savings program. Have your MA or care coordinator:

Call LEO Pharma at 877-678-7494 to inquire about the current savings card program.

Visit the LEO Pharma website to check current eligibility criteria (commercially insured patients only; government insurance excluded).

Provide the patient with the savings card before they leave the office, or ensure they have the phone number to enroll.

Strategy 4: PruGen Solutions Manufacturer Program (Generic)

PruGen Pharmaceuticals, a manufacturer of generic azelaic acid, operates a savings program where eligible commercially insured patients may pay no more than $25 per prescription. This program requires your enrollment as a prescriber. Contact PruGen to determine eligibility and enrollment requirements for your practice.

Strategy 5: Prior Authorization — Do It Early, Do It Right

When PA is required, the quality and timing of the request directly impacts cost outcomes. Late PA submissions result in prescriptions sitting unfilled, which often leads to abandonment. Best practices:

Submit the PA request the same day the prescription is written.

Include the rosacea ICD-10 code (L71.9 or appropriate variant), severity level, and prior treatment history.

If the patient has previously tried metronidazole, document that explicitly — this is the most common step therapy requirement.

Tell the patient to use a discount coupon in the interim if the PA will take 24–72 hours.

Strategy 6: Appeal Denials Proactively

If a PA for azelaic acid is denied on step therapy grounds, the appeal process can be supported by clinical evidence. Key arguments:

Head-to-head RCT data shows azelaic acid 15% gel is significantly superior (P = 0.005) to metronidazole 0.75% gel in reducing erythema and inflammatory lesions in rosacea.

A 2025 systematic review and meta-analysis found azelaic acid has a better overall efficacy profile than metronidazole for papulopustular rosacea.

If the patient is already stable on azelaic acid, document that switching carries a clinical risk of disease flare and request a step therapy exception.

Strategy 7: Patient Assistance Programs for Uninsured Patients

For uninsured patients, direct them to:

NeedyMeds.org: Database of manufacturer and foundation patient assistance programs for azelaic acid.

Medicine Assistance Tool (MAT): PhRMA's resource at mattool.org for locating assistance programs by drug.

Office samples: Request samples of Finacea from drug reps to provide starter supply to uninsured patients while assistance applications are processed.

Quick Prescribing Reference for Cost Optimization

Best for most patients: "Azelaic acid 15% gel, 50g, generic acceptable" + advise GoodRx ($27) or SingleCare ($38).

Commercially insured patients needing foam: LEO Pharma savings card (877-678-7494).

Insured patients on generic: PruGen Solutions program ($25/fill) — requires provider enrollment.

Uninsured patients: NeedyMeds.org or MAT + GoodRx coupon for generic while applying.

PA pending: Tell patient to use GoodRx coupon for generic in the interim — don't let them wait without treatment.

Help Patients Find Their Medication

Even when cost is managed, patients may still struggle to find the pharmacy that has their medication in stock. medfinder for providers can help your patients locate which pharmacies near them can fill their Finacea prescription. Consider recommending it as part of your standard patient handout for rosacea medications. See also: Finacea Shortage: What Providers Need to Know in 2026